Sectoral Asset Management as of Dec. 31, 2014
Portfolio Holdings for Sectoral Asset Management
Sectoral Asset Management holds 64 positions in its portfolio as reported in the December 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Biogen Idec (BIIB) | 6.7 | $149M | 439k | 339.45 | |
| Amgen (AMGN) | 6.4 | $143M | 895k | 159.29 | |
| Celgene Corporation | 5.7 | $127M | 1.1M | 111.86 | |
| BioMarin Pharmaceutical (BMRN) | 5.1 | $113M | 1.3M | 90.40 | |
| Incyte Corporation (INCY) | 4.4 | $97M | 1.3M | 73.11 | |
| Mylan | 3.8 | $86M | 1.5M | 56.37 | |
| Teva Pharmaceutical Industries (TEVA) | 3.6 | $79M | 1.4M | 57.51 | |
| Regeneron Pharmaceuticals (REGN) | 3.4 | $76M | 186k | 410.25 | |
| Alexion Pharmaceuticals | 3.2 | $71M | 386k | 185.03 | |
| Actavis | 3.0 | $66M | 257k | 257.41 | |
| Thermo Fisher Scientific (TMO) | 2.9 | $65M | 521k | 125.29 | |
| Gilead Sciences (GILD) | 2.9 | $65M | 684k | 94.26 | |
| Ptc Therapeutics I (PTCT) | 2.6 | $59M | 1.1M | 51.77 | |
| NPS Pharmaceuticals | 2.6 | $58M | 1.6M | 35.77 | |
| Shire | 2.2 | $50M | 236k | 212.54 | |
| Keryx Biopharmaceuticals | 2.1 | $46M | 3.3M | 14.15 | |
| Amicus Therapeutics (FOLD) | 1.8 | $40M | 4.8M | 8.32 | |
| Mallinckrodt Pub | 1.8 | $40M | 401k | 99.03 | |
| Perrigo Company (PRGO) | 1.7 | $39M | 232k | 167.16 | |
| Dr. Reddy's Laboratories (RDY) | 1.7 | $39M | 763k | 50.45 | |
| Pfizer (PFE) | 1.7 | $38M | 1.2M | 31.15 | |
| Halozyme Therapeutics (HALO) | 1.6 | $36M | 3.7M | 9.65 | |
| Seattle Genetics | 1.6 | $36M | 1.1M | 32.13 | |
| Medivation | 1.6 | $36M | 357k | 99.61 | |
| Oncomed Pharmaceuticals | 1.6 | $35M | 1.6M | 21.76 | |
| Allergan | 1.6 | $35M | 163k | 212.59 | |
| Synageva Biopharma | 1.5 | $34M | 364k | 92.79 | |
| Portola Pharmaceuticals | 1.4 | $32M | 1.1M | 28.32 | |
| Achillion Pharmaceuticals | 1.3 | $29M | 2.4M | 12.25 | |
| Intercept Pharmaceuticals In | 1.3 | $28M | 182k | 156.00 | |
| Acceleron Pharma | 1.2 | $28M | 714k | 38.96 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.1 | $25M | 212k | 118.80 | |
| Relypsa | 1.1 | $25M | 811k | 30.80 | |
| Clovis Oncology | 1.1 | $24M | 424k | 56.00 | |
| Medtronic | 1.0 | $22M | 310k | 72.20 | |
| United Therapeutics Corporation (UTHR) | 0.9 | $21M | 163k | 129.49 | |
| Sagent Pharmaceuticals | 0.9 | $21M | 834k | 25.11 | |
| Karyopharm Therapeutics (KPTI) | 0.9 | $20M | 530k | 37.43 | |
| Abbott Laboratories (ABT) | 0.8 | $18M | 405k | 45.02 | |
| Intuitive Surgical (ISRG) | 0.8 | $18M | 34k | 528.94 | |
| Momenta Pharmaceuticals | 0.8 | $18M | 1.5M | 12.04 | |
| Align Technology (ALGN) | 0.8 | $17M | 309k | 55.91 | |
| Akorn | 0.7 | $16M | 434k | 36.20 | |
| Dex (DXCM) | 0.7 | $16M | 286k | 55.05 | |
| NxStage Medical | 0.7 | $15M | 807k | 17.93 | |
| HeartWare International | 0.6 | $12M | 169k | 73.43 | |
| Hca Holdings (HCA) | 0.5 | $11M | 144k | 73.39 | |
| Novo Nordisk A/S (NVO) | 0.3 | $7.8M | 185k | 42.32 | |
| Amphastar Pharmaceuticals (AMPH) | 0.3 | $7.7M | 660k | 11.61 | |
| Universal Health Services (UHS) | 0.3 | $6.9M | 62k | 111.26 | |
| Cymabay Therapeutics | 0.3 | $7.0M | 709k | 9.83 | |
| Inogen (INGN) | 0.3 | $6.5M | 207k | 31.37 | |
| Novartis (NVS) | 0.3 | $5.9M | 64k | 92.66 | |
| Alder Biopharmaceuticals | 0.1 | $3.0M | 104k | 29.09 | |
| Prosensa Hldgs B V Shs Usd | 0.1 | $2.1M | 111k | 18.75 | |
| Zs Pharma | 0.1 | $2.0M | 48k | 41.57 | |
| Accuray Incorporated (ARAY) | 0.1 | $1.7M | 226k | 7.55 | |
| Advaxis | 0.1 | $1.7M | 211k | 8.01 | |
| Tandem Diabetes Care | 0.1 | $1.7M | 131k | 12.70 | |
| WuXi PharmaTech | 0.1 | $1.4M | 40k | 33.66 | |
| Uniqure Nv (QURE) | 0.1 | $1.4M | 94k | 14.81 | |
| Eleven Biotherapeutics | 0.1 | $1.3M | 113k | 11.88 | |
| Immune Design | 0.0 | $652k | 21k | 30.78 | |
| Valeant Pharmaceuticals Int | 0.0 | $258k | 1.8k | 143.33 |
